Viracta | Investor Relations

Month Year

Investor Alerts

Nov 13, 2024

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data...
Nov 6, 2024

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, November 6, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage...
Sep 5, 2024

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, September 3, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Aug 14, 2024

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val’s...
Aug 14, 2024

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val’s...
May 17, 2024

Viracta Therapeutics Announces New Employment Inducement Grants

San Diego, May 17, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
May 14, 2024

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

San Diego, May 14, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
May 9, 2024

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell...
May 7, 2024

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 7, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Apr 15, 2024

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable population) with a generally manageable safety profile -

San Diego, April 15, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Apr 1, 2024

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat...
Mar 7, 2024

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study expected in the second quarter of 2024

San Diego, March 7, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Feb 29, 2024

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

Accelerated pace of enrollment supports speed to market strategy

San Diego, February 29, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Feb 6, 2024

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

San Diego, February 6, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Jan 4, 2024

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential accelerated approval pathway by mid-2024

San Diego, January 4, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Dec 12, 2023

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

First orphan drug designation for Nana-val granted in EBV+ solid tumors

SAN DIEGO December 12, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Dec 4, 2023

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val

SAN DIEGO December 4, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Nov 9, 2023

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40%

SAN DIEGO, November 9, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Nov 7, 2023

Viracta Therapeutics to Present at Upcoming Investor Conferences

San Diego, November 7, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Oct 4, 2023

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

Preliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median duration of response extended to 17.3 months

SAN DIEGO October 4, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Sep 5, 2023

Viracta Therapeutics to Host R&D Day on October 4, 2023

SAN DIEGO September 5, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Aug 18, 2023

Viracta Therapeutics Announces New Employment Inducement Grant

San Diego, August 18, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Aug 14, 2023

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val

San Diego, August 14, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Aug 8, 2023

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the most aggressive cancers

SAN DIEGO, Calif August 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...
Aug 7, 2023

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

SAN DIEGO, Calif., August 7, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Jun 28, 2023

Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial

San Diego, June, 28, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
May 31, 2023

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

San Diego, May 31, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
May 11, 2023

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

San Diego, May 11, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
May 8, 2023

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

San Diego, May 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
May 2, 2023

Viracta Therapeutics Announces Departure of Chief Medical Officer

San Diego, May 2, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Apr 19, 2023

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

San Diego, April 19, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Mar 13, 2023

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023

San Diego, March 13, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Mar 8, 2023

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

San Diego, March 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Feb 7, 2023

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

San Diego, February 7, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Jan 19, 2023

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

Sixth orphan drug designation for Nana-val globally; second granted by the European Commission

San Diego, January 19, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Jan 8, 2023

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into fourth dose level is ongoing

San Diego, January 8, 2023 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Nov 30, 2022

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to determine the optimal recommended Phase 2 dose

San Diego, November 30, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Nov 21, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

San Diego, November 21, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Nov 14, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

San Diego, November 14, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Nov 10, 2022

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to Stage 2 now anticipated in the first half of 2023

San Diego, November 10, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...
Nov 2, 2022

Viracta Therapeutics to Present at Upcoming Investor Conferences

San Diego, November 2, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is scheduled to...
Sep 19, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

San Diego, September 19, 2022 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with the...
Sep 19, 2022

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of...
- Photos 1
Sep 7, 2022

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma

First orphan drug designation granted for Nana-val by the European Commission; fifth globally SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision...
Aug 16, 2022

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr...
Aug 11, 2022

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to...
Aug 9, 2022

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) expanding into Stage 2 is anticipated...
Jun 13, 2022

Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston, M.D.,...
Jun 2, 2022

Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting

Trial has advanced to the second dose escalation cohort with no dose-limiting toxicities observed to-date SAN DIEGO, June 2, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a...
Jun 1, 2022

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the Jefferies...
May 13, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors...
May 11, 2022

Viracta Therapeutics to Present at Upcoming May Investor Conferences

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one...
May 10, 2022

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) that have advanced into Stage...
Apr 20, 2022

Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors

Virtual event to take place on Wednesday, April 27, 2022, at 11:00 AM EDT SAN DIEGO, April 20, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company...
Apr 7, 2022

Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21st Annual...
Mar 18, 2022

Viracta Therapeutics Announces New Employment Inducement Grant

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors...
Mar 16, 2022

Viracta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma featured in an oral...
Mar 9, 2022

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to participate in a fireside...
Feb 10, 2022

Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, the company's President and Chief Executive...
Jan 31, 2022

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

First clinical trial to evaluate the safety and efficacy of Nana-val beyond lymphoma

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the first patient has been dosed in the multinational Phase...
Jan 4, 2022

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C....
Dec 16, 2021

Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology...
Dec 13, 2021

Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021

Vecabrutinib enhanced the efficacy of CAR T-cells in a murine mantle cell lymphoma model

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the presentation of new preclinical data on vecabrutinib, a...
Dec 13, 2021

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

Complete responses (CR) observed across multiple Epstein-Barr virus-positive (EBV+) lymphoma subtypes; overall response rate (ORR)/CR of 60%/27% in T/NK-NHL and 67%/33% in DLBCL

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that final data from its Phase 1b/2 trial of Nana-val in...
Nov 29, 2021

Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma

Fourth U.S. FDA orphan drug designation granted for Nana-val

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted its...
Nov 10, 2021

Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Announced that final results of Phase 1b/2 trial of nanatinostat and valganciclovir (Nana-val) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma were selected for an oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the third quarter of 2021 and provided an...
Nov 5, 2021

Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced that the Company has entered into a loan and...
Nov 4, 2021

Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting

Final results from the Phase 1b/2 trial of nanatinostat and valganciclovir (Nana-val) in relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma - selected for an oral presentation

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company primarily focused on targeting virus-associated malignancies, today announced the acceptance of two abstracts for oral...
Nov 1, 2021

Viracta Therapeutics to Present at Upcoming Investor Conferences

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one...
Oct 6, 2021

Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Multinational trial expands Viracta's clinical-stage pipeline beyond EBV+ lymphoproliferative disorders

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of a multinational Phase 1b/2 trial in patients with...
Sep 7, 2021

Viracta Therapeutics to Present at Upcoming Investor Conferences in September

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and be available for virtual...
Aug 23, 2021

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China

Viracta now controls global rights to its all-oral combination regimen of nanatinostat and valganciclovir

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and...
Aug 16, 2021

Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointments of Flavia Borellini, Ph.D., and Jane F. Barlow,...
Aug 12, 2021

Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

Initiated NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the second quarter of 2021 and provided...
Jul 21, 2021

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Third combination trial with nanatinostat and valganciclovir broadens scope beyond EBV+ lymphoproliferative disorders

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Jul 6, 2021

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific...
Jun 28, 2021

Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been added as a member of the small-cap Russell 2000®...
Jun 1, 2021

Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Now open for enrollment, NAVAL-1 is a multicenter basket trial with an adaptive Simon 2-stage design

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of NAVAL-1 (Nanatinostat in Combination with...
May 27, 2021

Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies...
May 18, 2021

Viracta Therapeutics to Host Key Opinion Leader Webinar

Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and...
May 12, 2021

Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma is on track to be initiated in Q2 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced financial results for the first quarter of...
Apr 8, 2021

Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual...
Mar 23, 2021

Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

Viracta to Receive $13.5 Million Upfront Cash Payment

Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) announced today XOMA has purchased the potential future milestones and royalties associated with existing licenses...
- Photos 2
Mar 11, 2021

Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of...
Mar 4, 2021

Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team

Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments...
Mar 3, 2021

Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life...
Feb 24, 2021

Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX'

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc....
Feb 16, 2021

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Resulting patent to extend Viracta's intellectual property protection into at least 2040

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has...
Feb 11, 2021

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci...
Dec 7, 2020

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

Promising data show complete responses observed across multiple subtypes of Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL

PR Newswire, San Diego, December 7, 2020 - Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent...
Nov 30, 2020

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., November 30, 2020 (GLOBE NEWSWIRE) - Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology...
Oct 8, 2020

Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

PR Newswire, San Diego, October 8, 2020 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston,...
Sep 14, 2020

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors

Viracta Therapeutics, Inc. ("Viracta" or the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as...
Sep 9, 2020

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of...
Jul 20, 2020

Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic Advisor

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish, MD, PhD, has joined Viracta as a...
Jul 14, 2020

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD to its Board of Directors

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors....
Jul 9, 2020

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions

Resulting patent to extend Viracta's intellectual property protection

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance...
Jun 24, 2020

Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma

PR Newswire, San Diego, June 24, 2020 - Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination...
May 28, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma

Call Will Feature Ronald Levy, MD (Stanford University) and Pierluigi Porcu, MD (Thomas Jefferson University)

SAN DIEGO, May 28, 2020 - Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader...
Apr 8, 2020

Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive...

Show per page

News Releases

Explore

Contact

Follow

Legal